content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001754424</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001737287</issuerCik>
        <issuerName>Allogene Therapeutics, Inc.</issuerName>
        <secFileNumber>001-38693</secFileNumber>
        <issuerAddress>
          <com:street1>210 EAST GRAND AVENUE</com:street1>
          <com:city>SOUTH SAN FRANCISCO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>(650) 457-2700</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>MESSEMER DEBORAH M.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Merrill Lynch</name>
          <address>
            <com:street1>225 Liberty St</com:street1>
            <com:street2>Floor 37</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10281</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>18640</noOfUnitsSold>
        <aggregateMarketValue>50316.67</aggregateMarketValue>
        <noOfUnitsOutstanding>168276662</noOfUnitsOutstanding>
        <approxSaleDate>12/18/2023</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <acquiredDate>12/13/2023</acquiredDate>
        <natureOfAcquisitionTransaction>Vesting of restricted stock unit award</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Allogene Therapeutics, Inc.</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>18640</amountOfSecuritiesAcquired>
        <paymentDate>12/13/2023</paymentDate>
        <natureOfPayment>Granted as part of issuer equity compensation plan</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <noticeSignature>
        <noticeDate>12/18/2023</noticeDate>
        <planAdoptionDates>
          <planAdoptionDate>06/28/2023</planAdoptionDate>
        </planAdoptionDates>
        <signature>Deborah Messemer</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2967}]
text: 144
  0001754424
  XXXXXXXX
  LIVE
  0001737287
  Allogene Therapeutics, Inc.
  001-38693
  210 EAST GRAND AVENUE
  SOUTH SAN FRANCISCO
  CA
  94080
  (650) 457-2700
  MESSEMER DEBORAH M.
  Director
  Common Stock
  Merrill Lynch
  225 Liberty St
  Floor 37
  New York
  NY
  10281
  18640
  50316.67
  168276662
  12/18/2023
  NASDAQ
  Common Stock
  12/13/2023
  Vesting of restricted stock unit award
  Allogene Therapeutics, Inc.
  N
  18640
  12/13/2023
  Granted as part of issuer equity compensation plan
  Y
  12/18/2023
  06/28/2023
  Deborah Messemer